Dr. Corey Langer Discusses Erlotinib in Advanced NSCLC
Onclive today, Jan 15,2012...titled as above.
Dr Langer's proposition that Erlotinib be considered for frontline therapy in EGFR positive patient populations in NSCLC bodes well for Cabo, as Cabo has proven NSCLC efficacy once Erlotinib treatment displays it's often-recognized resistance in long-term NSCLC therapy. Regardless of what the shorts would have you believe, Cabo will have it's day in the sun.
Nomad "bite my crank" Celcius can do just as his name suggests....
I have an unusually enjoyable piece of DD to share w/ you. It is a rare pleasure to find that your due diligence carries you into the path of a remarkably talented celebrity, but such is this tale. It remains one of my primary reasons for staying long behind EXEL. It is a wonderful story of courage and determination.
Google this: "Zheng Cao Mezzo Soprano Lung Cancer xl-184".
For starters, you are looking for an ABC news article dated 11/11/2010. Complete with streaming video, this a wonderful expository piece on an incredible turnaround story of a relatively young operatic diagnosed w/ NSCLC. As remarkable as is the story, so is the documented fast-acting effect of xl-184... and the commentary by Stanford clinician Dr Heather Wakelee. This story has been followed by a variety of news sources over the past couple years - the more you look, the more you'll find.
For instance, you can easily find that Zheng's diagnosis is EGFR positive.
Although I realize that a single success does not make the entire case, this story makes such a compelling case for Cabo in a post-erlotinib setting...I couldn't resist sharing it once again. Zheng is indeed a remarkable woman to proactively share her story with all who would care to listen.
If you get the opportunity - listen to her sing. Absolutely amazing...